secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001140361-24-010098
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore FY2023 KIMMTRAK sales $238.7M; launches PRAME Phase 3 with BMS
-------------------------------------------------------------------------

- Q4 2023 KIMMTRAK net sales $67.6M; full year $238.7M (+12% YoY). US $169.8M, Europe $67.6M.
- Net loss FY2023 $55.3M ($1.13 loss per share) vs $52.5M in 2022. R&D $163.5M, SG&A $144.5M.
- Cash $442.6M at Dec 31; raised $389.3M net in Feb 2024 via 2.5% convertible notes due 2030.
- Entered collaboration with BMS for Phase 3 PRISM-MEL301 trial of IMC-F106C + nivolumab in 1L advanced melanoma; first patient Q1 2024.
- Multiple PRAME data readouts in 2024: cutaneous melanoma (Q2), ovarian (Q3), NSCLC (Q4). KIMMTRAK now in 12 launched countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124010098/0001140361-24-010098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124010098/ef20022689_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-010098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer